European Archives - Page 855 of 982 - European Medical Journal

New Janssen Phase 3 Data in Patients with Moderately to Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression and Improves Signs and Symptoms of Disease

London, United Kingdom, 8 June, 2016 – Janssen Research & Development, LLC (Janssen) announced today results from a pivotal Phase 3 study evaluating…

New Data Demonstrates Sandoz’ Etanercept and Rituximab Biosimilar Candidates Bioequivalent to Originator Products

Holzkirchen, June 9 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from two key studies…

EMJ

T Cell Protein Provides New Leads in Understanding Immune Response

AN INNOVATIVE new study has uncovered a protein that is fundamental to controlling immune responses, which could provide much needed clarification of…

EMJ

New Insight into the Components of Pollen Proves Positive for Hay Fever Sufferers

NON-ALLERGENIC components of pollen do impact the body’s immune system, a recent study has uniquely revealed. The discovery could transform the future…

Artificial Hip Joints and Obesity: Risk of Complications Rises with BMI but Benefits Predominate

Geneva, 2 June 2016 – Every tenth patient who receives an artificial hip joint in Europe is obese. This is a big challenge for orthopaedic surgery…

Learning from Actual Practice: Registry Studies Promote Quality Treatment

Geneva, 1 June 2016 – What kinds of prosthetic joints are frequently used in a specific country? How durable are they and how often do they cause…

Prevention Is the Key: EFORT Calls for Better Frameworks to Keep People Moving and Active

Geneva, 1 June 2016 – Keeping people active, mobile and pain-free throughout life, and the contribution orthopaedics can make in an ageing society are…

Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis from Two Phase III Studies for Anamorelin in Cachectic Patients with Non-Small Cell Lung Cancer (NSCLC)

Lugano, Switzerland, June 1, 2016 – Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announces that it will present…

Janssen’s IMBRUVICA®▼(Ibrutinib) Approved by European Commission for Patients with Newly Diagnosed Chronic Lymphocytic Leukaemia

Beerse/Belgium, 31 May, 2016 – Janssen-Cilag International NV (Janssen) announced today that the European Commission (EC) has approved IMBRUVICA®…

European Commission Approves TREVICTA®(Paliperidone Palmitate a 3-Monthly Injection), for Maintenance Treatment of Schizophrenia

BEERSE, BELGIUM, 31st May 2016 – Janssen-Cilag International NV announced today that the European Commission (EC) has approved the use of TREVICTA®…